Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

ServiceNow vs. Workday: Here's What Revenue Growth Trends Between These Software Companies Tell Investors

Key PointsServiceNow demonstrates stronger overall revenue generation than Workday, leading the comparison in every consecutive quarter over the last two years.

ServiceNow (NOW) and Workday (WDAY), two leading cloud-based software companies, are both experiencing growth in revenue from their enterprise-level offerings. ServiceNow generates revenue by delivering workflow automation solutions, while Workday provides human capital management and financial software applications. Both firms have seen a rise in customer adoption, particularly in services leveraging artificial intelligence capabilities.

ServiceNow reported a revenue increase of 24% year-over-year in its second quarter, with sales reaching $4 billion. This growth can be attributed to the firm's AI offerings, which generated over $1 billion in annual contract value (ACV). Furthermore, 23% more of ServiceNow's customers surpassed $5 million in ACV during the same period, highlighting the company's ability to attract and retain high-value clients.

Workday also demonstrated solid revenue growth, increasing its sales by 13% year-over-year to $3.7 billion in its second quarter. A significant portion of this growth, 25%, came from AI-driven capabilities within its platform. Despite facing a class action lawsuit over algorithmic bias in its hiring tools, Workday has managed to remain a stable player in the back-office software market.

In conclusion, both ServiceNow and Workday are demonstrating consistent revenue growth, indicating strong demand for their enterprise software solutions. ServiceNow's revenue growth is outpacing Workday's, suggesting that the company may have a stronger pricing power and ability to attract high-spending clients. Nonetheless, Workday's focus on AI-driven capabilities and stable revenue growth positions it as a durable enterprise software provider.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

Where Will CRISPR Therapeutics Stock Be in 2030?

The company's expertise in gene editing could lead to more breakthroughs.

  • CRISPR Therapeutics stock declined 47% since mid-2021 while S&P 500 gained 73%.
  • Received approval for Casgevy, first CRISPR-based gene-editing therapy in 2023.
  • Promising pipeline candidates include LDL cholesterol reducer CTX310 and anticoagulant CTX611.

More from Sunday 18 October →